Atoltivimab is a fully human monoclonal antibody of the IgG1kappa isotype. It is not used alone but is a component of a fixed-dose, three-antibody combination product, Inmazeb (along with maftivimab and odesivimab). This combination is the first FDA-approved treatment for infection caused by Zaire ebolavirus (Ebola virus). Atoltivimab contributes to the antiviral activity by targeting the viral surface glycoprotein. Its mechanism includes both direct neutralization of the virus by blocking entry into host cells and Fc-mediated immune effector function (such as ADCC), which recruits host immune cells to destroy both the virus and infected cells. The multi-antibody approach ensures binding to three different, non-overlapping epitopes on the virus.